Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up

<div>(a) Long-term mean BCVA (all patients). (b) Mean BCVA in subgroup of patients with at least 5 years of follow-up. Note: variance is expressed in form of standard error of the mean; data depicted as dotted lines must be interpreted with caution as it represents a sample size of <i>n</i> &lt; 30. <sup>∗</sup>ETDRS and Snellen equivalents were calculated from LogMAR values.</div>

Journal of Ophthalmology

fig1

Figure 1

Figure 1: Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up 

Figure 1 | Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up 